Effective implementation will require greater provision of tests, services, and support Asthma is a common inflammatory airway condition that affects around six million people in the UK.1 Despite ...

Ravijyot Saggu explores key updates and implications of the new joint chronic asthma guidelines for diagnosis and monitoring.

Airsupra (PT027), a new asthma rescue treatment developed by AstraZeneca (AZ) and development partner Avillion, has been approved by the US Food and Drug Administration (FDA). A first-in-class ...

There is therefore a search for new therapies, particularly safe and effective oral treatments and those that are more efficacious in severe asthma. New therapies in development include mediator ...

After some disappointing earlier results for GSK’s new asthma treatment Revlar Ellipta, the company has today announced some encouraging news. An open-label non-inferiority lung function study ...

Sravani Meka, Senior Pharmaceutical Analyst at GlobalData, commented: “The current treatment approaches for severe asthma are primarily biologics, administered intravenously or subcutaneously.

A major new asthma drug has not been approved in over a decade, highlighting the critical need for new treatments like ENV-294 to address unmet patient needs." To accelerate the development of ENV ...

Ethris announces promising phase 1 results for ETH47, its mRNA therapy for uncontrolled asthma. The inhaled treatment showed ...

a new study ... Women With Asthma Are More Likely to Miscarry and Need Fertility Treatment Sep. 10, 2024 — Women who are being treated for asthma are more likely to miscarry and need fertility ...

The SARS-CoV-2 pandemic interrupted much respiratory research. Respiratory clinical academics joined colleagues in providing clinical care, and global research efforts were directed to finding new ...

This finding gives new insights into what drives severe asthma and points to potential new treatment targets. By understanding the role of these intermediate ILC2s, researchers hope to develop ...

A Victorian-based company is using AI to help “map” and personalise the best treatment for patients with respiratory conditions such as asthma, chronic obstructive pulmonary disorder and chronic ...